

ORIGINAL ARTICLE

# Identification of the involvement of LOXL4 in generation of keratocystic odontogenic tumors by RNA-Seq analysis

Wei-Peng Jiang<sup>1</sup>, Zi-Han Sima<sup>1</sup>, Hai-Cheng Wang<sup>1</sup>, Jian-Yun Zhang<sup>1</sup>, Li-Sha Sun<sup>2</sup>, Feng Chen<sup>2</sup> and Tie-Jun Li<sup>1</sup>

Keratocystic odontogenic tumors (KCOT) are benign, locally aggressive intraosseous tumors of odontogenic origin. KCOT have a higher stromal microvessel density (MVD) than dentigerous cysts (DC) and normal oral mucosa. To identify genes in the stroma of KCOT involved in tumor development and progression, RNA sequencing (RNA-Seq) was performed using samples from KCOT and primary stromal fibroblasts isolated from gingival tissues. Seven candidate genes that possess a function potentially related to KCOT progression were selected and their expression levels were confirmed by quantitative PCR, immunohistochemistry and enzyme-linked immunosorbent assay. Expression of lysyl oxidase-like 4 (LOXL4), the only candidate gene that encodes a secreted protein, was enhanced at both the mRNA and protein levels in KCOT stromal tissues and primary KCOT stromal fibroblasts compared to control tissues and primary fibroblasts ( $P < 0.05$ ). *In vitro*, high expression of LOXL4 could enhance proliferation and migration of the human umbilical vein endothelial cells (HUVECs). There was a significant, positive correlation between LOXL4 protein expression and MVD in stroma of KCOT and control tissues ( $r = 0.882$ ). These data suggest that abnormal expression of LOXL4 of KCOT may enhance angiogenesis in KCOT, which may help to promote the locally aggressive biological behavior of KCOT.

*International Journal of Oral Science* (2013) 6, 31–38; doi:10.1038/ijos.2013.96; published 20 December 2013

**Keywords:** angiogenesis; keratocystic odontogenic tumor; lysyl oxidase-like 4; RNA-sequencing; tumor stromal fibroblast

## INTRODUCTION

Keratocystic odontogenic tumors (KCOT) are benign, intraosseous tumors of odontogenic origin, with a characteristic lining of parakeratinized, stratified squamous epithelium and locally aggressive behavior.<sup>1</sup> In some patients, KCOT are associated with nevoid basal cell carcinoma syndrome.<sup>2</sup> The traditional designation for KCOT has been as an odontogenic keratocyst, which emphasizes the cystic nature of these lesions.<sup>3</sup> Previous studies demonstrated that *PTCH1*, a tumor-suppressor gene mapping to chromosome 9q22.3–q31, is involved in KCOT etiology.<sup>4</sup> However, since germline mutations in *PTCH1* are less frequent in patients with sporadic KCOT than in those with nevoid basal cell carcinoma syndrome-related KCOT, the pathogenesis of KCOT remains poorly characterized.

The stroma of KCOT has been reported to promote tumor progression.<sup>5</sup> Fibroblasts are the major component of stromal cells and secrete various cytokines, chemokines and extracellular matrix proteins to form the microenvironment that stimulates epithelial cell growth.<sup>6–7</sup> Several notable differences exist between KCOT stroma and control tissues. For example, the microvessel density (MVD) in KCOT stroma is greater than that in control tissues from dentigerous cysts (DC) or normal oral mucosa.<sup>8</sup> The stromal collagen fibers of KCOT also differ from those found in DC, but are similar to those seen in unicystic ameloblastoma.<sup>9–10</sup> Furthermore, greater osteoclastogenic capacity

was detected in KCOT fibroblasts cocultured with Raw264.7 cells.<sup>11</sup> These findings support the hypothesis that the stroma of KCOT should be recognized not only as structural support of the cyst wall, but also as a contributory factor to the neoplastic behavior of the cyst.

The advent of massive parallel sequencing technology has provided a powerful tool to study transcriptome changes through RNA sequencing (RNA-Seq).<sup>12</sup> By sequencing the entire transcriptome of tumors and matched control tissues, their expression levels can be compared.<sup>13–14</sup> RNA-Seq has a wider range of detection and higher sensitivity than microarrays and does not require advance knowledge of sequence information. In this study, we used RNA-Seq to explore the role of the stroma in KCOT pathogenesis and the progression of angiogenesis.

## MATERIALS AND METHODS

### Patient samples

We selected two fresh tissue specimens of mandibular adult-type KCOT from a female, aged 19 years, and a male, aged 35 years, index patient based on pathological diagnosis and clinical features. We also collected two excess healthy gingival tissue (GG) specimens from a female, aged 22 years, and a male, aged 29 years, after extraction of the third molar (wisdom tooth). No clinical signs of inflammation or bone destruction were evident in these healthy volunteers. Stromal fibroblasts were isolated and cultured as described previously.<sup>11</sup> All

<sup>1</sup>Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China and <sup>2</sup>Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China

Correspondence: Dr TJ Li, Department of Oral Pathology, Peking University School and Hospital of Stomatology, 22 South Zhongguancun Avenue, Beijing 100081, China

E-mail: litiejun22@vip.sina.com

Dr F Chen, Central Laboratory, Peking University School and Hospital of Stomatology, 22 South Zhongguancun Avenue, Beijing 100081, China

E-mail: moleculecf@gmail.com

Accepted 12 November 2013

samples were acquired at Peking University, Hospital of Stomatology, following institutional review board approval of their use for RNA-Seq analysis.

### Preparation of cDNA and sequencing

Preparation of cDNA and RNA-Seq was performed as shown in Supplementary Figure S1.

### Alignment statistics

Clean reads from the KCOT and control samples were mapped to the reference genome and gene sequences using SOAP2—a significantly improved version of the short oligonucleotide alignment program that both reduces computer memory usage and increases alignment speed at an unprecedented rate.<sup>15</sup> Mismatches no larger than  $m$  bases (default  $m$  value=5) were allowed in the alignment.<sup>16</sup> Allowing a smaller number of two or three mismatches did not affect the analysis (data not shown). Only reads that mapped uniquely were included in the analysis, unless indicated otherwise.

### Candidate gene filtering and mRNA expression validation

We filtered the data for genes expressed at abnormal levels in the stroma of KCOT compared to controls ( $F$  values  $\leq 0.001$ ), as described previously,<sup>17</sup> to identify those that may play a role in the pathogenic levels of angiogenesis observed in KCOT patients.

The mRNA levels of candidate genes were quantified using quantitative PCR (QPCR). QPCR was performed on a 7500 Fast System (Applied Biosystems, Foster City, CA, USA) according to a previously described protocol.<sup>18</sup> All primers were purchased from Invitrogen (Carlsbad, CA, USA) and are summarized in Supplementary Table S1.

### Immunohistochemistry

Twenty formalin-fixed and paraffin-embedded KCOT and DC tumors were obtained from primary surgeries in the Department of Pathology, Peking University School and Hospital of Stomatology. Ten normal GG tissues from wisdom teeth extractions were also collected to serve as controls.

The protocol for lysyl oxidase-like (LOXL4) and CD105 immunohistochemical analysis was based on Weise and Gadbaill.<sup>8–19</sup> Polyclonal rabbit anti-human LOXL4 (1:2000; ab88186; Abcam, Cambridge, UK) and CD105 (1:30; ZM-0297; Beijing Zhongshan, Beijing, China) were used as the primary antibodies. Each section was accompanied by positive and negative controls. Positive controls consisted of human pancreas for LOXL4 and human tonsil for CD105. Negative controls were obtained by omission of the primary antibody and replacement with non-immune serum. The slides were independently reviewed by two observers (TJL and FC) to confirm the analysis.

We randomly selected six fields at  $\times 100$  magnification, and counted cells at  $\times 400$  magnification. Cells with cytoplasmic staining with diaminobenzidine were considered positive for LOXL4. CD105 analysis was carried out using an Olympus BX51 research microscope (Olympus, Tokyo, Japan). CD105-positive vascular endothelial cells were clearly identified by brown cytoplasmic staining. Distinct countable microvessels were assessed using the criteria described by Jaeger.<sup>20</sup> MVD of the adjacent connective tissue was measured using the method of Gadbaill.<sup>8</sup>

### Enzyme-linked immunosorbent assay

Due to the availability of material, LOXL4 levels were measured by enzyme-linked immunosorbent assay (ELISA) in both primary fibroblast cell supernatants and cell lysates. A commercially available ELISA

kit (E95554Hu; Uscn, Houston, TX, USA) for LOXL4 was used according to the manufacturer's instructions. The plates were read at an absorbance of 450 nm using a Spectra Max Plus plate reader (ELx808; BioTek, Winooski, VT, USA). Results were normalized to the number of tested cells by measuring the protein concentration of each sample before the ELISA using the Pierce BCA Protein Assay Kit (Thermo, Boston, MA, USA). Measurements were performed in triplicate.

### Construction of expression plasmid LOXL4

Human LOXL4 cDNA was purchased from Sino Biological and cloned in pCMV/hygro (CV004; Sino Biological, Beijing, China) for transient overexpression with a DNA Ligation Kit (2011A; TAKARA, Kyoto, Japan).

### Western blot analysis

Total protein lysates from human umbilical vein endothelial cells (HUVECs) were resolved on 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), then transferred to nitrocellulose membrane or polyvinylidene fluoride membrane, and underwent immunoblotting with LOXL4 antibody (1:2000; ab88186; Abcam, Cambridge, UK). The secondary antibodies were goat anti-rabbit at 1:5000 (1:2000; sc2004; Santa Cruz Biotechnology, Dallas, TX, USA).

### Endothelial cell proliferation assay

HUVECs ( $1 \times 10^4$  cells per well) were cultured for 24 h in 96-well tissue culture plates (Corning, New York, NY, USA) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and  $0.1 \text{ mg} \cdot \text{mL}^{-1}$  heparin. Cell proliferation was measured by Cell Counting Kit-8 (Dojindo, Tokyo, Japan).

### Endothelial cell transmigration assay

For the scratching assay, HUVECs ( $8 \times 10^5$  cells in 3 mL DMEM) were seeded in 60-mm diameter culture dishes. The medium was changed to serum-free OPTI.MEM the next morning for synchronization. Four hours later, scratching was made and fresh medium without FBS was added. Five fields were randomly selected in each dish for recording gap distances immediately following scratching and 6 h afterwards.

For Boyden chamber assay, 200  $\mu\text{L}$  of HUVECs suspension ( $2 \times 10^4 \text{ mL}^{-1}$  in DMEM without FBS) was placed in the upper chamber, and 600  $\mu\text{L}$  DMEM with 10% FBS was placed in the lower chamber. After incubation for 4 h, the cells on the upper surface were removed, and the cells on the underside were fixed and stained. Each treatment was performed in triplicate wells, and the mean number of cells in each well was counted from four randomly chosen fields under light microscopy ( $\times 200$ ).

### Statistical analysis

Data are the means of three individual experiments performed in triplicate and analyzed using one-way analysis of variance, a Student's  $t$ -test for independent samples, a Bonferroni test for multiple comparisons and a Pearson's rank correlation test.  $P$  values  $< 0.05$  were considered to indicate statistical significance.

## RESULTS

### Sequence enrichment

The RNA-Seq reads were first aligned based on a method described previously.<sup>21</sup> The majority of reads from each sample (77.36%–84.88%) aligned successfully to the human genome (Table 1). The sequences that

**Table 1 Summary of sequence enrichment during RNA-Seq of keratocystic odontogenic tumors and normal gingival tissues**

Map to genome/gene	Map to genome		Map to gene	
	Reads number	Percentage/%	Reads number	Percentage/%
<b>KCOT</b>				
Total reads	52 388 976	100.00	52 388 976	100.00
Total basepairs	4 715 007 840	100.00	4 715 007 840	100.00
Total mapped reads	44 465 709	84.88	40 525 636	77.36
Perfect match	33 038 565	63.06	40 525 636	62.69
≤5 bp mismatch	11 427 144	21.81	7 685 059	14.67
Unique match	41 833 042	79.85	25 314 413	48.32
Multiposition match	2 632 667	5.03	15 211 223	29.04
Total unmapped reads	7 923 267	15.12	11 863 340	22.64
<b>GG</b>				
Total reads	49 781 578	100.00	49 781 578	100.00
Total basepairs	4 480 342 020	100.00	4 480 342 020	100.00
Total mapped reads	41 916 300	84.20	38 531 845	77.40
Perfect match	31 149 590	62.57	31 168 655	62.61
≤5 bp mismatch	10 766 710	21.63	7 363 190	14.79
Unique match	39 587 698	79.52	24 309 783	48.83
Multiposition match	2 328 602	4.68	14 222 062	28.57
Total unmapped reads	7 865 278	15.80	11 249 733	22.60

GG, gingival primary stromal fibroblast cells; KCOT, keratocystic odontogenic tumors; RNA-seq, RNA-sequencing.

**Table 2 Genes identified as up-regulated or down-regulated by RNA-Seq and microarray analysis**

Regulation	Protein location	Biological functions	Synonyms	RNA-Seq	Microarray			
Up	Extracellular	Related to ECM formation and degradation	LOXL4	1.586 5	3.174 3			
			SUSD2	5.498 1	1.918 6			
			NPB	2.444 6	1.974 1			
		Other functions	TCTA	1.817 8	1.504			
			LARP6	2.004	1.735 9			
			ZBTB32	102.989 1	1.608 2			
	Intracellular	Other functions	HCST	5.070 3	1.994 1			
			HCP5	1.957 2	2.169 9			
			UCHL1	1.830 2	1.636 9			
			MBNL3	1.730 4	1.573 9			
			ZNF671	1.694 1	1.503 2			
			ADCY4	1.599 1	3.774 6			
			RDH5	1.595 3	1.550 1			
			Down	Intracellular	Related to cell proliferation and apoptosis	KIT	4.258 5	4.790 4
						TNFRSF25	3.598 5	1.562
RGS12	1.796 5	1.527 2						
RICTOR	1.721 9	1.859 1						
Other functions	GLRX	1.822 3				1.661 3		
	MAG12	1.798 4				1.514 9		
			FEM1B	1.585 7	1.672 7			
			IQSEC2	1.572 4	1.593 7			

ECM, extracellular matrix; LARP6, La ribonucleoprotein domain family, member 6; LOXL4, lysyl oxidase-like 4; RNA-Seq, RNA sequencing; TCTA, T-cell leukemia translocation-associated gene.

did not align are likely to be polyclonal, of low quality, or have origins outside the reference human genome.


**RNA-Seq analysis of gene expression in KCOT, DC and normal gingival tissues**

We compared the RNA-Seq data to microarray results from our laboratory (data not shown), which compared the mRNA levels in six primary KCOT stromal fibroblasts to those in six DC. Genes up- or downregulated in both the RNA-Seq and microarray data were selected for further analysis (Table 2). We selected candidate genes with a function potentially related to KCOT generation (Figure 1 and Table 3). As secreted proteins may affect adjacent tumor epithelial cells, we focused on LOXL4, a copper-containing amine oxidase,

which belongs to the LOX family, as it was the only one of the seven candidate genes that encoded a secreted protein.

**Verification of RNA-Seq results**


QPCR analysis was performed to confirm the RNA-Seq and microarray results by verifying mRNA expression levels of the seven candidate genes (Table 3). The expression levels of *LOXL4*, T-cell leukemia translocation-associated gene (*TCTA*), La ribonucleoprotein domain family, member 6 (*LARP6*) and regulator of G-protein signaling 12 (*RGS12*) in three samples of KCOT primary stromal fibroblasts, GG stromal primary fibroblasts and DC stromal primary fibroblasts were consistent with the RNA-Seq and microarray data ( $P < 0.05$ ; Figure 2a). There were no significant differences among the expression levels of



**Figure 1 Search outline for candidate genes identified by RNA-Seq.** Genes differentially expressed in KCOT, primary SC and healthy GG were first identified by RNA-Seq. The RNA-Seq results were compared to microarray data, which was performed to identify differentially expressed genes in KCOT primary stromal fibroblasts and in DC primary SC (data not shown). The genes were then subjected to further selection based on their function, to identify candidate genes that may affect the progression of KCOT. DC, dentigerous cysts; GG, gingival primary stromal fibroblast cells; KCOT, keratocystic odontogenic tumors; RNA-Seq, RNA sequencing; SC, stromal fibroblast cell.

*KIT*, *TNFRSF25* and *RICTOR* in stromal primary fibroblasts ( $P > 0.05$ ; data not shown). To confirm the expression of the candidate gene *LOXL4*, we quantified the expression of *LOXL4* mRNA in three groups: five healthy GG samples, three DC samples and five KCOT samples. All

stromal fibroblasts were derived from freshly isolated tissues. The expression of *LOXL4* mRNA was significantly higher in the KCOT tissues than in the DC (3.7-fold) and GG (2.3-fold) tissues ( $P < 0.05$ ; Figure 2b), consistent with the RNA-Seq and microarray results.




**Figure 2 Confirmation of RNA-Seq results.** (a) QPCR analysis of TCTA, LARP6, RGS12 and *LOXL4* mRNA expression in primary stromal fibroblasts of KCOT, DC and healthy GG. The data were consistent with the RNA-Seq and microarray results. (b) QPCR analysis of *LOXL4* mRNA expression in primary stromal fibroblasts of KCOT, DC and GG. Each bar corresponds to the mean  $\pm$  s.d. of three independent experiments performed in triplicate with three technical repeats. \* $P < 0.05$ , \*\* $P < 0.001$ . DC, dentigerous cysts; GG, gingival primary stromal fibroblast cells; KCOT, keratocystic odontogenic tumors; LARP6, La ribonucleoprotein domain family, member 6; *LOXL4*, lysyl oxidase-like 4; QPCR, quantitative PCR; RGS12, regulator of G-protein signaling 12; RNA-Seq, RNA sequencing; TCTA, T-cell leukemia translocation-associated gene.

**Table 3 Candidate genes possibly involved in keratocystic odontogenic tumor progression**

Name	RNA-Seq	Microarray	Regulation	Function
LARP6	2.004 039	1.735 885 1	Up	Regulates the coordinated translation of type I collagen alpha-1 and alpha-2 mRNAs, CO1A1 and CO1A2
LOXL4	1.856 549	3.174 347 4	Up	Modulate the formation of a collagenous extracellular matrix
TCTA	1.817 763 9	1.503 996 7	Up	Required for cellular fusion during osteoclastogenesis
KIT	4.258 54	4.790 408	Down	This is the receptor for stem cell factor (mast cell growth factor)
TNFRSF25	3.598 541	1.561 969	Down	The protein encoded by this gene is a member of the TNF-receptor superfamily
RGS12	1.796 471	1.527 165	Down	This protein may play a role in tumorigenesis
RICTOR	1.721 887	1.859 07	Down	Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals

ECM, extracellular matrix; LARP6, La ribonucleoprotein domain family, member 6; LOXL4, lysyl oxidase-like 4; RGS12, regulator of G-protein signaling 12; TCTA, T-cell leukemia translocation-associated gene; TNF, tumor-necrosis factor.



**Figure 3 LOXL4 is overexpressed in the stroma of KCOT.** (a) LOXL4 concentration in the supernatants of primary fibroblasts derived from KCOT, GG and DC ( $n=3$  per tissue) by ELISA. (b) LOXL4 concentration in the cell lysates of primary fibroblasts derived from KCOT, GG and DC ( $n=3$  per tissue) by ELISA. Data are the means of triplicates from a representative experiment  $\pm$  s.d.; \* $P<0.05$ , \*\* $P<0.001$ . DC, dentigerous cysts; ELISA, enzyme-linked immunosorbent assay; GG, gingival primary stromal fibroblast cells; KCOT, keratocystic odontogenic tumors; LOXL4, lysyl oxidase-like 4.

### LOXL4 protein expression is upregulated in KCOT fibroblasts

LOXL4 protein levels were quantified in the supernatants and lysates of nine primary stromal fibroblast cell lines (three KCOT, three DC and three normal GG tissues) by ELISA. LOXL4 was detected in all nine fibroblast cell line supernatants and lysates (Figure 3a and 3b). The LOXL4 protein level was significantly higher in the supernatants and lysates of KCOT stromal fibroblasts than in stromal fibroblasts derived from DC or GG tissues. Compared to KCOT stromal fibroblasts, the levels of LOXL4 were 2.47- and 2.04-fold lower in DC and GG stromal fibroblast supernatants, respectively, and 3.46- and 2.87-fold lower in DC and GG stromal fibroblast lysates, respectively (Figure 3b;  $P<0.001$ ).

### Immunohistochemical analysis of LOXL4

Immunohistochemical analysis was performed to quantify LOXL4 protein expression in KCOT, DC and GG tissue samples. Few fibroblasts in DC and GG tissues expressed LOXL4, and the immunoreactivity was faint or weak (Figure 4a1, 4a2, 4a4 and 4a5). However, intense LOXL4 immunostaining was observed in the cytoplasm of stromal fibroblasts in KCOT tissues (Figure 4a7 and 4a8). We also identified significant differences in the numbers of cells stained by LOXL4 and the MVD of the KCOT, DC and GG samples ( $P<0.05$ ).

Previous studies have confirmed that the LOX family members LOX and LOXL2 can enhance angiogenesis *in vivo* and *in vitro*.<sup>22-23</sup> As a member of the LOX family, LOXL4 has a similar structure to LOX and LOXL2, so we hypothesized that it may also be related to angiogenesis. We used CD105, a marker of angiogenesis, to quantify angiogenesis in the stroma of KCOT, DC and GG tissues. CD105 was expressed in 100% of KCOT stromal endothelial cells, 45.73% of DC stromal

endothelial cells and 52.68% of GG stromal endothelial cells. Similar to LOXL4, the quantity of CD105-positive vessels was higher in the stroma of the KCOT samples than the DC and GG tissues (Figure 4a3, 4a6 and 4a9).

Comparison of the three groups by one-way analysis of variance revealed a statistically significant difference ( $P<0.001$ ). Bonferroni analysis did not indicate a significant difference in LOXL4 and MVD between the DC and GG samples ( $P=0.358$ ). However, the differences between KCOT samples and DC ( $P<0.001$ ) and GG ( $P<0.001$ ) samples were statistically significant. Significant positive correlations were observed between the LOXL4 and MVD in all three groups (correlation coefficient ( $r$ )=0.882;  $P<0.001$ ; Figure 4a and Table 4).


**Table 4 Microvessel density and LOXL4 in keratocystic odontogenic tumors, dentigerous cysts and gingival tissues**

Groups	$n$	Mean	Standard deviation	Minimum	Maximum
MVD KCOT	20	30.10	10.67	11.50	47.49
DC	20	12.17	5.37	5.79	11.61
GG	10	8.70	7.69	8.63	16.75
LOXL4 KCOT	20	37.97	7.71	15.39	47.38
DC	20	15.58	3.67	6.36	23.53
GG	10	11.32	5.58	3.25	14.83

DC, dentigerous cysts; GG, gingival primary stromal fibroblast cells; KCOT, keratocystic odontogenic tumors; LOXL4, lysyl oxidase-like 4; MVD, microvessel density.

MVD was calculated as number of microvessels ( $1 \times 10^6 \mu\text{m}^{-2}$ ).





**Figure 4** Effects of LOXL4 on angiogenesis. (a) LOXL4 expression and microvessel density in DC, GG and KCOT stroma. Immunohistochemical analysis of LOXL4 (a1, a2, a4, a5). Few LOXL4-positive fibroblasts were observed in GG (a1, a2) or DC (a4, a5). (a7, a8) Most of the KCOT stromal fibroblasts were strongly LOXL4-positive. (a3, a6) Few CD105-positive microvessels were observed adjacent to the epithelium of normal GG (a3) and dentigerous cysts (a6). A high density of strongly CD105-positive microvessels was found in the stroma immediately beneath the epithelium lining KCOT (a9). The intensity of LOXL4 protein expression was consistent with the density of CD105-positive microvessels in GG (a3), DC (a6) and KCOT (a9). Scale bar=100  $\mu$ m. (b) Effects of LOXL4 on the proliferation and migration of HUVECs. (b1, b2) There was a significant increase in the expression of LOXL4 both in intracellular and extracellular of HUVECs transfected with LOXL4 than transfected with empty plasmid. (b3) Transient LOXL4 transfection increased cell growth, cell proliferation was measured with Cell Counting Kit-8 at 6, 12, 24, 72 and 96 h. (b4) HUVECs migration ability was assessed by scratching assay with or without LOXL4 transfection. Representative images are shown (magnification:  $\times$ 100). (b5) HUVECs migration ability was also tested by Boyden Chamber assay with or without LOXL4 transfection. Representative images are shown (magnification:  $\times$ 200). Each treatment was triplicate and six fields were randomly chosen from each well for counting mean number of migrated cells. Data are presented as mean  $\pm$  s.e.m., \* $P$ <0.05, \*\* $P$ <0.01, Student's  $t$ -test. DC, dentigerous cysts; ELISA, enzyme-linked immunosorbent assay; GG, gingival primary stromal fibroblast cells; HUVEC, human umbilical vein endothelial cell; KCOT, keratocystic odontogenic tumors; LOXL4, lysyl oxidase-like 4; OD, optical density; Ctl, control.

### Effects of LOXL4 on HUVEC proliferation study

HUVEC proliferation study was used to evaluate the effect of LOXL4 *in vitro*. Anti-LOXL4 antibodies were used to detect exogenous LOXL4 protein, respectively. LOXL4 protein expression (Figure 4b1 and 4b2) was higher in HUVECs transfected with LOXL4 than in control groups (transfected with empty plasmid). Transient overexpression of LOXL4 significantly induced cell proliferation in comparison to control cells (Figure 4b3).

### Effects of LOXL4 on HUVEC migration study

HUVEC migration study was assessed by Transwell assay. As shown in Figure 4b4, the number of cells that crossed the membrane in the LOXL4 overexpression groups was significantly higher than in the control groups.

Scratching assays were also performed to determine whether transient LOXL4 expression would also affect the endothelial migration. Figure 4b5 indicated that LOXL4 could promote HUVECs' migration.

## DISCUSSION

In 1956, Philipsen<sup>24</sup> first described a cyst of the jaw lined by keratinizing epithelium, which was termed an odontogenic keratocyst. Based on its unique clinicopathological features, such as aggressive growth within the jaws, tendency to invade surrounding anatomical structures and occasional malignant alteration,<sup>25</sup> the World Health Organization reclassified odontogenic keratocyst as KCOT in 2005.<sup>26</sup> A considerable number of previous studies attributed the highly neoplastic nature of KCOT to the epithelium.<sup>4,27–29</sup> However, no persuasive evidence indicates that the epithelium plays a significant role in KCOT. Increasing evidence supports the argument that tumor microenvironment plays a major role in all phases of tumorigenesis, including initiation, progression, maintenance and metastasis, and may also influence therapeutic outcome. In 1975, Browne<sup>5</sup> first proposed that the connective tissue wall plays a significant role in the pathogenesis of KCOT. Recently, differences in angiogenesis, collagen fibers and osteoclastogenic ability have been identified in the stroma of KCOT and control tissues.<sup>6–11</sup>

In 2011, Gadbail *et al.*<sup>8</sup> found that the MVD and the Ki-67 labeling index were significantly higher in the stroma of KCOT than DC and normal oral mucosa, with a significant positive correlation between the Ki-67 and MVD.<sup>8</sup> This suggests that angiogenesis is associated with the locally aggressive biological behavior of KCOT.

Collagen is a major component of the extracellular matrix (ECM). In a pathological setting, collagen contributes to diameter and cross-sectional profile of individual fibers. Hirshberg *et al.*<sup>30</sup> has shown that the polarization color pattern of collagen fibers in the connective tissue stroma of KCOT differs from DC. Zhang *et al.*<sup>9</sup> reported that the stromal collagen fibers of KCOT were different from those of subcutaneous epidermoid cysts, but similar to those of unicystic ameloblastoma using picosirius red staining.<sup>9</sup> These findings lend further support to the hypothesis that KCOT should be regarded as a cystic neoplasm rather than a cyst.<sup>26,30–31</sup>

When osteoclast precursor Raw264.7 cells are cocultured with fibroblasts from KCOT fibrous capsule and gingival mucosa, a significantly higher number of osteoclast-like cells were observed in the KCOT coculture system than in the gingival coculture system.<sup>11</sup> This suggests that KCOT fibroblasts may be involved in the bone resorption process by interacting with osteoclast precursors and enhances osteoclastogenesis.

However, the mechanisms leading to differences in KCOT stroma remain elusive. To investigate how mesenchymal cells affect the

progression of KCOT, we compared the results of RNA-Seq, which compared KCOT stromal fibroblasts with GG stromal fibroblasts, and a microarray analysis which compared KCOT stromal fibroblasts with DC stromal fibroblasts. We filtered the data to identify differentially expressed genes that may play a role in the progression of KCOT, particularly angiogenesis, collagen remodeling and osteoclastogenesis (Table 2 and Figure 2). Based on this analysis, we focused on LOXL4, which encodes a secreted protein that may affect neighboring tumor cells.

LOXL4 was first shown to function as a copper-dependent amine oxidase which catalyzes lysine-derived crosslinks in ECM proteins, and increased expression of LOXL4 has been reported in various of tumors.<sup>32</sup> We demonstrated that KCOT stromal cells express higher intracellular and extracellular levels of LOXL4 protein than DC or GG stromal cells (Figure 3), indicating that LOXL4 may play a more important role in KCOT stromal cells than in DC or GG stromal cells. Two other LOX family members (LOX and LOXL2), which have similar sequences and structures to LOXL4, are known to promote angiogenesis,<sup>22–23</sup> leading to the hypothesis that LOXL4 may also participate in angiogenesis. In this study, the mean number of microvessels was significantly higher in KCOT tissues than DC or GG tissues, which corresponds to other reports.<sup>8,33–34</sup> Transient LOXL4 overexpression in HUVECs confirmed LOXL4-enhanced HUVEC proliferation and migration *in vitro* (Figure 4b3, 4b4 and 4b5). We also found that MVD was significantly and positively correlated with LOXL4 expression in the stroma of KCOT, DC and GG. This suggests that increased expression and secretion of LOXL4 by stromal cells is related to tumor angiogenesis in KCOT, which in turn may facilitate the locally aggressive biological behavior of this tumor type.<sup>8</sup>

Other candidate genes may play roles in KCOT progression by altering the tumor microenvironment. TCTA may be required for cellular fusion during osteoclastogenesis, and polyclonal antibodies against TCTA could inhibit both human osteoclastogenesis from monocytes and fusion of mature osteoclasts.<sup>35</sup> This suggests that the high levels of TCTA expression in KCOT stroma may favor osteoclastogenesis. LARP6 could regulate the coordinated translation of type I collagen alpha-1 and alpha-2 mRNAs, CO1A1 and CO1A2, and stabilize the mRNAs through high-affinity binding of a stem-loop structure in their 5' UTR. The high expression of LARP6 in KCOT stroma may play a role in the development of tissue fibrosis by stabilizing collagen mRNAs.<sup>36–37</sup> RGS12 may play a role in tumorigenesis by increasing the GTPase activity of G-protein alpha subunits, thereby driving them into their inactive GDP-bound form to inhibit signal transduction.<sup>38</sup> Aberrant RGS aberrant plays a pivotal role in vascular maturation and vessel remodeling.<sup>39</sup> Moreover, RGS12 is essential for the terminal differentiation of osteoclasts induced by RANKL.<sup>40</sup>

In summary, our data demonstrate that abnormal expression of these novel genes in KCOT stromal cells may affect the tumor microenvironment by mediating angiogenesis, collagen remodeling and osteoclastogenesis. These findings support the hypothesis that the stroma of KCOT plays an important role in the neoplastic behavior of this tumor type, as well as providing structural support for the cyst wall. Due to the limited number of specimens used, further studies using other sophisticated methods and larger numbers of patient samples are required to clarify the role of these genes, particularly LOXL4, in KCOT progression. The identification of changes in LOXL4, TCTA, LARP6 and RGS12 expression in KCOT stroma and their potential function in angiogenesis, collagen remodeling and osteoclastogenesis will result in interest in these genes as targets for various KCOT treatment strategies.

## ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (grant nos. 81030018, 30872900 and 30901680) and the Doctoral Fund of Ministry of Education of China (grant no. 20120001110043). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

- 1 Mendes RA, Carvalho JF, van der Waal I. Biological pathways involved in the aggressive behavior of the keratocystic odontogenic tumor and possible implications for molecular oriented treatment—an overview. *Oral Oncol* 2010; **46**(1): 19–24.
- 2 Figueroa A, Correnti M, Avila M *et al*. Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type? *Otolaryngol Head Neck Surg* 2010; **142**(2): 179–183.
- 3 Shear MSP. *Cysts of the oral and maxillofacial regions*. Oxford: Blackwell Munksgaard, 2007.
- 4 Pan S, Dong Q, Li TJ *et al*. Mechanisms of inactivation of *PTCH1* gene in nevoid basal cell carcinoma syndrome: modification of the two-hit hypothesis. *Clin Cancer Res* 2010; **16**(2): 442–450.
- 5 Browne RM. The pathogenesis of odontogenic cysts: a review. *J Oral Pathol* 1975; **4**(1): 31–46.
- 6 Bhowmick NA, Moses HL. Tumour stroma interactions. *Curr Opin Genet Dev* 2005; **15**(1): 97–101.
- 7 Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. *Mol Med Today* 2000; **6**(8): 324–329.
- 8 Gadbaill AR, Hande A, Chaudhary M *et al*. Gondivkar. Tumor angiogenesis in keratocystic odontogenic tumor assessed by using CD-105 antigen. *J Oral Pathol Med* 2011; **40**(3): 263–269.
- 9 Zhang JY, Dong Q, Li TJ. Differences in collagen fibres in the capsule walls of parakeratinized and orthokeratinized odontogenic cysts. *Int J Oral Maxillofac Surg* 2011; **40**(11): 1296–1300.
- 10 Vij R, Vij H, Rao NN. Evaluation of collagen in connective tissue walls of odontogenic cysts—a histochemical study. *J Oral Pathol Med* 2011; **40**(3): 257–262.
- 11 Wang HC, Li TJ. The growth and osteoclastogenic effects of fibroblasts isolated from keratocystic odontogenic tumor. *Oral Dis* 2013; **19**(2): 162–168.
- 12 Tuch BB, Laborde RR, Xu X *et al*. Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. *PLoS ONE* 2010; **5**(2): 9317.
- 13 Mortazavi A, Williams BA, McCue K *et al*. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 2008; **5**(7): 621–628.
- 14 Wang ET, Sandberg R, Luo S *et al*. Alternative isoform regulation in human tissue transcriptomes. *Nature* 2008; **456**(7221): 470–476.
- 15 Li H, Handsaker B, Wysoker A *et al*. The sequence alignment/map format and SAMtools. *Bioinformatics* 2009; **25**(16): 2078–2079.
- 16 Levin JZ, Berger MF, Adiconis X *et al*. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. *Genome Biol* 2009; **10**(10): R115.1–R115.8.
- 17 Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009; **10**(1): 57–63.
- 18 Weise JB, Csiszar K, Gottschlich S *et al*. Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer. *Int J Oncol* 2008; **32**(2): 317–322.
- 19 Weise JB, Csiszar K, Gottschlich S *et al*. LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer. *Int J Oncol* 2008; **44**(9): 1323–1331.
- 20 Jaeger TM, Weidner N, Chew K *et al*. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. *J Urol* 1995; **154**(1): 69–71.
- 21 Wallerman O, Motalebipour M, Enroth S *et al*. Molecular interactions between HNF4a, FOXA2 and GABP identified at regulatory DNA elements through ChIP-sequencing. *Nucleic Acids Res* 2009; **37**(22): 7498–7508.
- 22 Shih YH, Chang KW, Chen MY *et al*. Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma. *Head Neck* 2012; **35**(2): 250–256.
- 23 Bignon M, Pichol-Thievend C, Hardouin J *et al*. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. *Blood* 2011; **118**(14): 3979–3989.
- 24 Philipsen HP. Om keratocystedr (kolesteratomer) i and kaeberne. *Tandlaegebladet* 1956; **60**: 963–971.
- 25 Jurisic M, Andric M, dos Santos JN *et al*. Clinical, diagnostic and therapeutic features of keratocystic odontogenic tumors: a review. *J BUON* 2012; **17**(2): 237–244.
- 26 Barnes L, Eveson J, Reichart P *et al*. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. *Ear Nose Throat J* 2006; **85**(2): 74.
- 27 Tsuneki M, Cheng J, Maruyama S *et al*. Perlecan-rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor. *J Oral Pathol Med* 2008; **37**(5): 287–293.
- 28 Pan S, Li TJ. *PTCH1* mutations in odontogenic keratocysts: are they related to epithelial cell proliferation? *Oral Oncol* 2009; **45**(10): 861–865.
- 29 Mendes RA, Carvalho JF, van der Waal I. A comparative immunohistochemical analysis of COX-2, p53, and Ki-67 expression in keratocystic odontogenic tumors. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011; **111**(3): 333–339.
- 30 Hirschberg A, Sherman S, Buchner A *et al*. Collagen fibres in the wall of odontogenic keratocysts: a study with picrosirius red polarization microscopy. *J Oral Pathol Med* 1999; **28**(9): 410–412.
- 31 Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 3. Immunocytochemistry of cytokeratin and other epithelial cell markers. *Oral Oncol* 2002; **38**(5): 407–415.
- 32 Scola N, Gorogh T. LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma. *Anticancer Res* 2010; **30**(11): 4567–4571.
- 33 el-Labban NG, Aghabeigi B. A comparative stereologic and ultrastructural study of blood vessels in odontogenic keratocysts and dentigerous cysts. *J Oral Pathol Med* 1990; **19**(10): 442–446.
- 34 Alaeddini M, Salah S, Dehghan F *et al*. Comparison of angiogenesis in keratocystic odontogenic tumours, dentigerous cysts and ameloblastomas. *Oral Dis* 2009; **15**(6): 422–427.
- 35 Kotake S, Nanke Y, Kawamoto M *et al*. T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis. *Bone* 2009; **45**(4): 627–639.
- 36 Manojlovic Z, Stefanovic. A novel role of RNA helicase A in regulation of translation of type I collagen mRNAs. *RNA* 2012; **18**(2): 321–324.
- 37 Challa AA, Stefanovic B. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. *Mol Cell Biol* 2011; **31**(18): 3773–3789.
- 38 Wang J, Lippman SM, Lee JJ *et al*. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. *Carcinogenesis* 2010; **31**(10): 1755–1761.
- 39 Manzur M, Hamzah J, Ganss R. Modulation of G protein signaling normalizes tumor vessels. *Cancer Res* 2009; **69**(2): 396–399.
- 40 Yang S, Li YP. RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts *in vitro*. *J Bone Miner Res* 2007; **22**(1): 45–54.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0>

Supplementary Information for this article can be found on *Light: Science & Applications* website (<http://www.nature.com/ijos/>)